Companies: 10,795·Total market cap: $144.5T
Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTONASDAQHealthcare
$0.30
+$0.30(+100.00%)
Market Cap$1133556
P/E Ratio—
52W High$0.4158
52W Low$0.3
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Altamira Therapeutics Ltd. (CYTO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001601936 · CYTO · NASDAQ · as of Jun 9, 2026

Filing snapshot

518
Total Filings
15-12G
Latest Form
2026-02-27
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001601936 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2025-04-30
Fiscal Year End
Apr 30, 2025
Accession No.
0001213900-25-037199
Primary Document
ea0237996-20f_altamira.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001601936 · Accession 0001213900-25-037199

Latest Key Filings

6-KQuarterly Report
REPORT OF FOREIGN PRIVATE ISSUER
2025-08-29
View 6-K on SEC
8-KCurrent Report
FORM 8-K12G3
2019-03-18Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
FORM 15-12B
2026-02-27
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2025-08-29
View
25-NSE25-NSE
25-NSE
2025-06-17
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2025-06-11
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-05-15
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2025-05-09
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2025-05-06
View
20-FAnnual Report (Foreign Issuer)
ANNUAL REPORT
2025-04-30
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2025-04-30
View
S-8Employee Stock Plan Registration
REGISTRATION STATEMENT
2025-04-04
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2025-03-10
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-14
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2024-12-20
View
SC 13GBeneficial Ownership Report
Beneficial Ownership Report
2024-11-14
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2024-10-04
View
Showing 1–15 of 518 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001601936  |  Exchange: NASDAQ · Healthcare

Altamira Therapeutics Ltd. (NASDAQ: CYTO) has submitted 518 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001601936, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Altamira Therapeutics Ltd.'s most comprehensive regulatory disclosure. The most recent Altamira Therapeutics Ltd. 10-K was filed on 2025-04-30 for fiscal year ending 2025. Historical CYTO 10-K annual reports are available from 2014 through 2025.

Investors researching Altamira Therapeutics Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
ONCT SEC Filings →NBSE SEC Filings →CWBR SEC Filings →TMBR SEC Filings →NVIV SEC Filings →IMPL SEC Filings →BLCM SEC Filings →INFIQ SEC Filings →
→ CYTO Financials→ CYTO Earnings→ CYTO Insider Trades

Frequently Asked Questions

CYTO SEC Filings · 8 questions

Altamira Therapeutics Ltd. (CYTO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 518 filings and access original documents at no cost. Altamira Therapeutics Ltd.'s CIK is 0001601936.

CYTO SEC filingsAltamira Therapeutics Ltd. SEC documentsfind CYTO 10-K